Imagene AI, an Israeli cancer diagnosis startup, raised $21.5 million in Series A funding for its cancer diagnosis platform-based digitized imaging of biopsy samples.
The round was led by Oracle co-founder Larry Ellison and fellow investors Dr. David Agus and Zebra Medical Vision founder Eyal Gura – including $3 million in seed funding from venture capital firm Blumberg Capital.
The proceeds of the financing will be used to develop Imagene AI’s platform, which promises to deliver real-time molecular analysis for biopsies, generating results in just two minutes compared to weeks with current approaches.
Company: Imagene AI Ltd.
Round: Series A
Funding Month: May 2022
Lead Investors: Larry Ellison, Dr. David Agus, and Eyal Gura
Company Website: https://imagene-ai.com/
Software Category: AI-based molecular diagnosis for cancer
About the Company: Imagene AI was founded in 2020 by Dean Bitan, Jonathan Zalach, and Shahar Porat, Imagene AI provides AI-based molecular diagnosis for cancer, leveraging the patient's histological data for personalized therapy. Imagene AI's mission is to assist cancer patients in receiving the optimal treatment medicine can offer by leveraging AI to detect, in real-time, a broad range of cancerous biomarkers and genomic insights from the biopsy image alone. By doing so, Imagene overcomes economical, logistical, and technological barriers to reach the full potential of precision medicine for cancer patients. Through collaborations with top-tier medical centers and pharmaceutical companies, Imagene is revolutionizing molecular screening for both clinical practice and research.